ComboMATCH trial—a collaboration across NCI and NCTN groups—matches patients with combination therapy trials based on tumor biology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NCI and all five cooperative groups that make up the National Clinical Trials Network have launched a large-scale precision medicine initiative that will match cancer patients with early-phase clinical trials testing novel drug combinations that target specific tumor alterations. 

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents